Predictive Value of Haematological Indices on Mortality in Patients with Empyema
Abstract
Background:Empyema is an infectious disease characterized by the accumulation of pus in the pleural space and accompanied by inflammation. Patients often present with fever, chest pain, dyspnea, or cough, and delayed diagnosis or treatment is associated with high mortality rates. Therefore, in this study, we aim to investigate the clinical utility of the Systemic Inflammation Response Index (SIRI), Pan-Immune Value (PIV), C-Reactive Protein (CRP)-Albumin-Lymphocyte (CALLY) index, and Systemic Immune-Inflammation Index (SII) in assessing the severity of empyema and predicting mortality risk.
Methods:Between January 2022 and October 2024, 73 patients diagnosed with empyema in the thoracic surgery clinic were included in the study. Patients were categorized based on the need for intensive care. Demographic and laboratory data (e.g., white blood cell count, platelet count, albumin levels, pleural fluid culture results, and C-reactive protein levels) were recorded. Differences between empyema patient groups, classified according to disease severity, were analyzed.
Results:Among the 73 patients included in our study, 4 deaths were recorded. It was observed that the CALLY index could be used for intensive care and ward triage (p:0.039). While the SII and SIRI indices were not suitable for triage purposes, the SIRI index was found to be useful for predicting mortality (p:0.01).
Conclusion:In empyema cases, the CALLY index can be used to determine the need for intensive care, while the SIRI index can help predict mortality risk.
References
2. Shen KR, Bribriesco A, Crabtree T, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. The Journal of thoracic and cardiovascular surgery. 2017;153(6):e129-e46.
3. Light RW. A new classification of parapneumonic effusions and empyema. Chest. 1995;108(2):299-301.
4. Higuchi M, Suzuki HJCCiTS. Current status and prospect of medical and surgical management for thoracic empyema. 2020. 2020;2.
5. Presti T, Asghar A, Ravikumar N. Management of Pleural Infection: A Historical Review and Updates. 2024;4(2):112-27.
6. Imburgio S, Tavakolian K, Mararenko A, et al. Empyema Versus Lung Abscess: A Case Report. J Investig Med High Impact Case Rep. 2022;10:23247096221139268.
7. Heffner JE, Klein JS, Hampson C. Diagnostic utility and clinical application of imaging for pleural space infections. Chest. 2010;137(2):467-79.
8. Pacheco-Barcia V, Mondejar Solis R, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 2020;20(2):254-64.
9. Feng JF, Chen S, Yang X. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus. Medicine (Baltimore). 2017;96(4):e5886.
10. Kayhan S, Aydın İsak Ö. The significance of pan-immune inflammation value and systemic immune inflammation Index in colorectal cancer screening. Turkish Journal of Clinics and Laboratory. 2021;12(3):273-7.
11. Shivappa N, Hebert JR, Marcos A, et al. Association between dietary inflammatory index and inflammatory markers in the HELENA study. Molecular Nutrition & Food Research. 2017;61(6):1600707.
12. Pre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer. Cancer management and research. 2022;Volume 14:2803-12.
13. Wei W, Jinyu G, Yanxiang L, et al. Pre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer. Cancer management and research. 2022;14:2803-12.
14. Tongchao J, Haishuang S, Shuyu X, et al. Significance of Pre-Treatment CALLY Score Combined with EBV-DNA Levels for Prognostication in Non-Metastatic Nasopharyngeal Cancer Patients: A Clinical Perspective. Journal of Inflammation Research. 2024.
15. Yao-Te T, Chien-An K, Hung-Chin C, et al. Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Oral Cavity Cancer. Journal of Cancer. 2022;13(10):3000-12.
16. Ying P, Ting W, Changbo D, et al. Association between the C-Reactive Protein–Albumin–Lymphocyte (CALLY) Index and Adverse Clinical Outcomes in CAD Patients after PCI: Findings of a Real-World Study. Reviews in Cardiovascular Medicine. 2024.
17. Yin X, Zhang Y, Zou J, et al. Association of the systemic immune-inflammation index with all-cause and cardiovascular mortality in individuals with rheumatoid arthritis. Scientific Reports. 2024;14(1):15129.
18. Marchi F, Pylypiv N, Parlanti A, et al. Systemic Immune-Inflammation Index and Systemic Inflammatory Response Index as Predictors of Mortality in ST-Elevation Myocardial Infarction. 2024;13(5):1256.
19. Topal A, Yarkaç A, Bozkurt S, et al. Prognostic importance of the systemic inflammatory index and the systemic inflammatory response index in COVID-19 patients. Emergency Care Journal. 2024;20(3).
20. Ren T, Zhou E, Wu J, et al. Systemic inflammation markers independently associated with increased mortality in individuals with hyperuricemia: Results from the NHANES prospective cohort study. 2024;12(10):e70032.
21. Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncology. 2017;3(12):e172319-e.
22. Gu L, Xia Z, Qing B, et al. Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001–2018). 2024;15.
Copyright (c) 2025 Ali Kutta Celik, Abdikani Ali SALAD, ökkeş zortuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.